• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Biogen (BIIB) Could Be 4% Undervalued After Strong Earnings And Product News

    Simply Wall St·09/27/2026 00:22:48
    Listen to the news

    Biogen (BIIB) has just combined a better than expected earnings print with fresh product news, including new LEQEMBI Pen approval in Japan and adolescent EMPAVELI data, giving investors several moving pieces to assess.

    Recent trading suggests investors are leaning into that story. The share price is up 5.6% over the past week and 28.0% year to date, while the 1-year total shareholder return of 65.7% contrasts with declines over the 3 and 5 year periods. This points to momentum that is only relatively recent.

    Scan for other healthcare names with fresh catalysts and recent momentum by jumping into our curated list of 38 healthcare AI stocks alongside Biogen's latest moves.

    Biogen has just reported stronger earnings and announced new product successes, and the share price has moved up quickly. Does that make this an early opportunity that justifies paying a higher price now, or a story to keep on the watchlist while waiting for a more attractive entry point?

    Most Popular Narrative: 4% Undervalued

    Biogen last closed at $227.60, while the most followed narrative pegs fair value at $236.22 using a 7.8% discount rate. That gap is modest in dollar terms, but the story behind it leans heavily on a handful of future therapies.

    Robust late-stage and diversified neurodegenerative and specialty disease pipelines, including Phase III launches in SMA, lupus, and kidney indications, capitalize on regulatory momentum to address high unmet needs. This creates multiple shots on goal that reduce future revenue volatility and support long-term earnings stability.

    See why 60 investors see Biogen as 4% undervalued.

    Result: Fair Value of $236.22 (UNDERVALUED)

    Still, the bullish Biogen narrative could be knocked off course if key launches like LEQEMBI or litifilimab stumble on safety concerns or slower than expected uptake.

    Find out about the key risks to this Biogen narrative.

    Another View: What Biogen’s P/E Is Telling You

    The SWS DCF model suggests Biogen is trading well below an estimated future cash flow value of $449.35, which points to a large implied upside. However, the current P/E of 40.3x is much higher than the US Biotechs sector at 17.1x, peers at 23.4x, and even the fair ratio of 29.2x. This raises the question of which signal to focus on when risk and optimism appear to pull in opposite directions.

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:BIIB P/E Ratio as at Sep 2026
    NasdaqGS:BIIB P/E Ratio as at Sep 2026

    Next Steps

    Mixed signals so far, with Biogen drawing both concern and optimism from different angles, so move quickly, sift through the figures, and weigh the 2 key rewards and 2 important warning signs.

    Looking For More Investment Ideas Beyond Biogen?

    Do not stop your research with Biogen. Broaden your watchlist with a few focused screens that surface different types of opportunities before the crowd gets there.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.